Market revenue in 2020 | USD 1,043.1 million |
Market revenue in 2030 | USD 3,494.9 million |
Growth rate | 12.9% (CAGR from 2020 to 2030) |
Largest segment | Mabs |
Fastest growing segment | MABs |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | MABs, Recombinant Protein |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, Boehringer Ingelheim, Lonza Group Ltd, AbbVie Inc, Catalent Inc, Merck & Co Inc, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Abzena, Samsung BioLogics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract manufacturing market will help companies and investors design strategic landscapes.
Mabs was the largest segment with a revenue share of 57.9% in 2020. Horizon Databook has segmented the Canada biologics contract manufacturing market based on mabs, recombinant protein covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada biologics contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Canada biologics contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account